Fol News

Tutti gli approfondimenti
Tutte le notizie

GNBT - Joe MOSCATO..........get going - tomo NOVE

Questa parte non mi piace per niente;

Per continuare le operazioni, avremo bisogno di fondi supplementari per sostenere le nostre esigenze di capitale circolante e le eventuali attività di sviluppo, o sarà necessario sospendere le operazioni. Gestione è alla ricerca di diverse alternative per garantire che siamo in grado di soddisfare alcune delle nostre esigenze di cash flow operativi attraverso attività di finanziamento, come ad esempio il collocamento privato delle nostre azioni ordinarie, offerte azioni privilegiate e offerta di strumenti di debito di debito e convertibili, nonché tramite fusioni o acquisizioni opportunità . Inoltre, la gestione è attivamente alla ricerca di alternative strategiche, compresi gli investimenti strategici e disinvestimenti. Abbiamo venduto il patrimonio immobiliare non essenziali che sono stati classificati tra le attività detenute per investimento per aumentare la nostra posizione di cassa. Non possiamo fornire alcuna garanzia che otterremo il finanziamento richiesto. La nostra incapacità di ottenere fondi necessari nel prossimo futuro, o la nostra incapacità di ottenere finanziamenti a condizioni favorevoli avrà un effetto negativo sulla nostra attività e il nostro piano di sviluppo strategico per la crescita futura. Se non siamo in grado di raccogliere con successo ulteriori capitali e mettere in atto il nostro piano di sviluppo strategico, la nostra liquidità, le condizioni finanziarie e di business prospettive saranno materialmente e negativamente colpiti

Pertanto siamo quasi falliti................
 
non c'è + nulla da raschiare...... o appaiono gli extra terrestri con portafogli pieni, o ciao ciao baby.
 
Generex Announces Closing of Acquisition of Controlling Equity Interest in Hema Diagnostic Systems
Company Also Announces New Management Slate
 
Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 19, 2017 it consummated the previously announced acquisition of a controlling equity interest in Hema Diagnostic Systems, LLC (www.hemadiagnosticsystems.com) (“HDS”). The Company filed a Form 8-K Current Report in respect of the acquisition with the U.S. Securities and Exchange Commission (SEC.gov | Home) on Friday, January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms and the business of HDS. It also includes the audited financial statements of HDS.

“The consummation of this significant acquisition and the establishment of a fresh and dynamic management team and Board represents a new beginning for Generex Biotechnology Corporation and its stockholders. I look forward to unveiling the Company’s strategic vision and plans over the course of the coming weeks and months.”
Tweet this
Hema Diagnostic Systems

HDS, a Florida corporation headquartered in a Food and Drug Administration (FDA)-registered facility in Miramar, Florida, develops, manufactures, and distributes proprietary in-vitro rapid diagnostics tests that address the global medical community’s need for simple, accurate, and affordable rapid diagnostic tests for infectious diseases such as HIV, tuberculosis, malaria, hepatitis, syphilis, typhoid, dengue, and others.

Pursuant to a formal Acquisition Agreement, Generex has acquired 51% of the issued and outstanding equity securities in the capital of HDS in exchange for shares of Generex common stock.

Dr. Jason Terrell, MD, Generex’s new Chief Scientific Officer and Medical Director, stated: “I’m thrilled to see Generex make this Hema Diagnostic Systems acquisition, along with its strong team and proven track record. Global utilization of diagnostics is always limited by cost and accessibility. HDS addresses these limitations through its affordable, rapid result, point-of-care platform technology systems. Generex and HDS will work together to expand the existing catalog of tests by applying the platform to additional areas of unmet need. This partnership has the potential to deliver a consistent stream of valuable products to patients worldwide.”

New Generex Management Slate

In concert with this acquisition, Generex is also pleased to announce a new slate of Directors and Executive Officers:

Name

Office(s) Held
Joseph Moscato
President, Chief Executive Officer, Chairman of the Board of Directors
Andrew Greene, Esq.
Chief Operating Officer, Director
Andrew Ro
Chief Investment Officer, Director
Lawrence Salvo
President and CEO of HDS, Senior Vice-President – Diagnostics, Director
Dr. Craig Eagle, MD
Independent Director
Dr. Gary H. Lyman, MD
Independent Director
Brian McGee
Independent Director, Chairman of the Audit Committee of the Board of Directors
Dr. James H. Anderson, Jr., MD
Independent Director
Dr. Jason Terrell, MD
Chief Scientific Officer, Chief Medical Director
Dr. Jacob Dagan, Ph.D.
Executive Vice-President – Development
Mark Corrao
Chief Financial Officer, Treasurer
Richard Purcell
Senior Vice-President – Research & Drug Development
Mark Fletcher, Esq.
Executive Vice-President, General Counsel, Secretary
Newly minted Generex President & Chief Executive Officer Joseph Moscato stated: “The consummation of this significant acquisition and the establishment of a fresh and dynamic management team and Board represents a new beginning for Generex Biotechnology Corporation and its stockholders. I look forward to unveiling the Company’s strategic vision and plans over the course of the coming weeks and months.”
 
Finalmente si muove qualcosa:
Moscato è ritornato e sono contento anche per Eagle, anche se si vocifera di un RS 1:1000
l'importante è che si muova qualcosa
 
e credo che un corposo RS potrebbe essere l'inizio per riconquistare il NASDAQ.....chissà
 
Io... 2,3 mil a 0,009$

Mi sto mangiando le mani x Non aver venduto a 0,0135$

Da una parte mi aspetto che se non nel breve, cmq nel medio ci sta graficamente una tradata sulla 200 weekly a 0,019$

Dall'altra parte, per ora è solo fufa... Non ci sono soldi... E non ci sono aggiornamenti sui farmaci....
 
Generex will purchase 51% percent of the issued and outstanding common stock of Emmaus (“Emmaus Shares”) at the closing of the Proposed Acquisition (the “Closing”), with an appropriate adjustment in the number of Emmaus Shares to maintain its 51% equity position in the event that any warrants, options or other convertible securities of Emmaus are subsequently exercised.

The purchase price for the Emmaus Shares will consist of $10,000,000 in cash and $215,000,000 worth of shares of Generex’s common stock (“Generex Shares”), which will be valued at $3.80 per share at the Closing, provided that if a material event occurs that increases the fair market value of Generex Shares prior to the Closing, the value attributed to the Generex Shares will be increased to such higher market value up to a maximum of $12.00 per share. This valuation assumes the consummation of a reverse stock split of Generex’s common stock at a 1000 to 1 ratio, and if such reverse stock does not occur or occurs on different terms, the per share price will be adjusted accordingly. The closing price of Generex’s common stock as of January 17, 2017 was $0.0047 per share.

In the event that (i) Emmaus does not receive the approval of the Food and Drug Administration (“FDA”) by July 7, 2017 (unless the approval date is extended by the FDA for administrative reasons beyond Emmaus’ control, in which case such later date of FDA approval shall apply) for its oral pharmaceutical grade L-glutamine treatment for sickle cell anemia and sickle ß0-thalassemia and (ii) additional requirements, including trials and testing, are required for FDA approval, then the foregoing purchase price may be adjusted in proportion to the funding needed from Generex to meet such additional requirements. The adjustment will be effected by Emmaus issuing additional Emmaus Shares to Generex or returning to Generex some of Generex Shares, in either case, in proportion to the amount of the necessary funding. Alternatively, Emmaus has the right to raise the necessary funding by sale of Generex Shares (subject to Generex’s right of first refusal) or issuance of Emmaus shares of common stock.

Generex has paid Emmaus an initial portion of the cash consideration in the amount of $500,000 and will pay Emmaus $1,500,000 within three (3) weeks of January 16, 2017. The $500,000 payment was advanced to Generex and was funded by Joseph Moscato, Generex’s new CEO and Director, and Lawrence Salvo, Generex’s new Senior Vice President and Director. Generex does not have any formal arrangement for repayment of the amounts advanced by Mr. Moscato and Mr. Salvo.

In addition, upon signing of a definitive purchase agreement (which the parties anticipate will occur within 45 days of January 16, 2017), Generex will pay Emmaus $2,000,000. The remaining $6,000,000 of the cash portion of the consideration will be paid at the Closing, which is contemplated to occur within 60 days of January 16, 2017. If the parties do not execute a definitive purchase agreement within such 45-day period or the Closing does not occur within such 60-day period, all cash payments are to be refunded to Generex, plus a breakup fee in the form of warrants to acquire Emmaus capital stock with a market value of $500,000 determined with a strike price corresponding to the Closing valuation of Emmaus at $450 million. The breakup fee shall be payable only if the failure to execute the definitive purchase agreement or close the Proposed Acquisition is not caused by Generex’s breach of its obligations.

Generex will grant Emmaus an option to acquire (or “earn back”) up to 36% of the Emmaus Shares which will be exercisable at an exercise price of $100 per 1% of Emmaus’ capital stock upon Emmaus achieving one of the following conditions (collectively, the “Emmaus Benchmarks”): (i) receiving approval of the FDA by July 7, 2017 (unless the approval date is extended by the FDA for administrative reasons beyond Emmaus’ control, in which case such later date of FDA approval shall apply), for its oral pharmaceutical grade L-glutamine treatment for sickle cell anemia and sickle ß0-thalassemia; or (ii) securing a contractual agreement with a pharmaceutical company to which Emmaus receives an upfront payment from the pharmaceutical company.
 
In pratica hanno fatto due accordi con due aziende per rilevare il 51% di entrambe.
Il costo più o meno è di 250milioni cad. Pagati in azioni gnbt

Per una delle due, entro due mesi devono pagare 10 milioni

Faranno reverse 1000 a 1

(*) io credo che ci sarà a breve una news consistente... Potrebbe essere accordo con una big per Antigen
Perché queste due aziende sono buone per il discorso oral-lyn
 
il sito a cui mi riferivo per le quotazioni real time degli OTC è saltato.
Avete qualche altro sito?
 
Devi accedere o registrarti per poter rispondere.
Indietro